ARCTIC BIOSCIENCE Aktie

 

Reference is made to the stock exchange release from earlier today, 1 April 2026 regarding new long-term financing, including agreements with shareholders who have provided guarantees for the new financing. The following companies closely related to primary insiders are a part of the shareholders which have provided guarantees for the new financing: · Ronja Capital AS, a company closely related to Board Member Tore Tønseth, NOK 10,0 million · Vartdal Holding AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,5 million · Brødrene Vartdal AS, a company closely...

Arctic Bioscience has secured new long-term financing through a bank loan of NOK 15 million. Together with previously disclosed increase in credit facility of NOK 8 million from December 2025, the company has increased available liquidity by a total of NOK 23 million. The new loan and the increased credit facility are secured through a growth guarantee from Innovation Norway of NOK 6 million and through guarantees from various shareholders of a total of NOK 18 million. Regarding guarantees from shareholders: Agreements have been entered into with shareholders who have provided...

Arctic Bioscience announces that new research on herring roe oil (HRO) and phospholipid esters from herring roe (PEHeRo) has been accepted for publication in the Journal of Lipid Research, an internationally recognized scientific journal in the field of lipid biology. The study shows that HRO and its phospholipids (PEHeRo) activates the body's own inflammation‑resolving mechanisms by increasing the production of specialized pro‑resolving mediators (SPMs) in human immune cells and in a skin cell model relevant for psoriasis. SPMs are naturally occurring molecules derived from omega‑3 fatty...

Highlights Q4 2025: · Strong ending to the year with quarterly sales revenue of NOK 13,9 million · Solid order intake into 2026 for the nutraceutical business · Positive pilot study related to glaucoma received international attention · Partner search and dialogues for HRO350 is given great attention · Cost-focus resulted in significantly lower operational costs in 2025 Arctic Bioscience had a strong ending to 2025 with quarterly revenue from the nutraceutical business of NOK 13,9 million. Total revenue for the year was somewhat lower than in 2024, ending at NOK 42,6 million....

Arctic Bioscience will publish its Q4 2025 operational update on Thursday 26[th] of February 2026, at 07:00 CET. The same day at 10:00 CET, the Company will host a webcast to present the operational update. Following the presentation, it will be opened for questions from the audience. Webcast details: Date: Thursday 26[th] of February 2026 Time: 10:00 CET Format: Webcast and Q&A Language: Norwegian/English The presentation can be accessed with the link below: https://events.teams.microsoft.com/event/14063048-ef68-47fa-a928-7b6060c7ee61@ce618813-5158-40b5-b6d0-...

Arctic Bioscience are pleased to announce that we have been invited to present at the Glaucoma 360 New Horizons Forum in San Francisco on January 30th 2026, in the session 'The Perfect Dose: Innovating Drugs and Drug Delivery'. Our Medical Director, Runhild Gammelsæter, will be presenting our latest pipeline project, ABS403, with the aim to promote resolution of inflammation and support neuroprotection in glaucoma. This eye disease does not currently have a cure and leads to blindness. The project was initiated based on encouraging clinical signals from a pilot study in glaucoma (POAG)....

Reference is made to the stock exchange release published by Arctic Bioscience 12th December 2025 regarding Board approval of share capital increase related to the exercise of debt conversion rights and corresponding issuance of new shares in Arctic Bioscience. The share capital increase has now been registered with the Norwegian Register of Business Enterprises. As a result, the new share capital of Arctic Bioscience has increased from NOK 2 685 934 to NOK 2 695 625,60, divided into 26 956 256 shares, each having a nominal value of NOK 0,10. This information is subject to the disclosure...

Reference is made to the stock exchange release published by Arctic Bioscience 9th December 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic Bioscience. On 12 December 2025, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company's General Meeting on 26[th] May 2025, resolved to increase the share capital from NOK 2 685 934 to NOK 2 695 625,60 by issuance of 96 916 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 2,789659405 per share, including a share premium of NOK...

With reference to the stock exchange notice of 13[th] of January 2025 regarding new financing via a convertible loan. An investor, which participated in the investor consortium contributing to the convertible loan of total NOK 15 million, has exercised his right to convert the outstanding debt into shares. Debt that will be converted is NOK 270 365. The conversion amount includes accrued interest. The conversion price is set at NOK 2,7896 per share based on the received conversion notice. The Board of Directors will issue the shares, pursuant to authorization granted by the Company's General...

An Extraordinary General Meeting in Arctic Bioscience AS was held Tuesday 11 November 2025 at 10:00 (CET). All the items on the agenda were addressed and approved. Attached is the minutes of the Extraordinary General Meeting. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act....

Highlights Q3 2025: · Analysis on HeROPA study shows statistically significant effects of psoriasis drug candidate HRO350 on inflammation · Significant vision improvement registered in Clinical Glaucoma Study based on ROMEGA® herring caviar oil – partner potential for further development and commercialization · Nutra revenues close to last year – despite significantly affected by the recall-situation earlier this year. Order intake remains strong for 2026 deliveries Arctic Bioscience recently disclosed new positive data from the HeROPA-trial in mild-to-moderate psoriasis. Analysis...

Arctic Bioscience will publish its Q3 2025 operational update on Monday 10[th] of November, at 07:00 CET. The same day at 10:00 CET, the Company will host a webcast to present the operational update and also results from the HeROPA-trial analysis. Following the presentation, it will be opened for questions from the audience. Webcast details: Date: Monday 10[th] of November 2025 Time: 10:00 CET Format: Webcast and Q&A Language: Norwegian/English The presentation can be accessed with the link below: https://events.teams.microsoft.com/event/a5afa4c4-2a3b-40e4-9137-...

Analysis on blood samples from the psoriasis HeROPA-trial revealed statistically significant effects of HRO350 versus placebo on Systemic Immune-inflammation Index (SII) in patients with mild-to-moderate psoriasis. Significantly more patients treated with HRO350 achieved a ≥ 25% reduction in a systemic inflammatory marker at both 26 weeks and 1 year compared to placebo. Among patients with lower baseline systemic inflammation, this reduction was accompanied by statistically significant improvements in psoriasis skin symptoms and quality of life, shown through achievement of sPGA0/1 and DLQI0/...

An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 11 November 2025 at 10:00 (CET), as a digital meeting. The agenda of the meeting is election of a new auditor for the Company. The elected auditor, PwC, has informed Arctic Bioscience AS of corporate reorganization that will result in a portion of their business, including partners, employees and clients, being moved to a wholly owned subsidiary. Arctic Bioscience AS is one of the clients that has been moved to the wholly owned subsidiary. The move does not entail any changes to the services provided. The...

Highlights H1 2025: · Encouraging top-line results from the HeROPA clinical study on key secondary endpoints · New long-term funding of NOK 30 million secured in January 2025 · Nutra revenues of NOK 17,2 million (NOK 16,7 million) with a gross margin of 33,4 % (30,6 %) · New skin care product launched – Romega Skin Refine set for international expansion · Operating costs reduced with NOK 6,4 million compared to first half 2024 · Improved adjusted EBITDA year to date in 2025, NOK -13,6 million (NOK -20,9 million) · Positive development in Arctic Algae with good progress...

Arctic Bioscience will publish its financial results for the first half year of 2025 on Thursday 28[th] of August, at 08:00 CET. The same day at 11:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience. Webcast details: Date: Thursday 28[th] of August 2025 Time: 11:00 CET Format: Webcast and Q&A Language: Norwegian/English The presentation can be accessed through the Company's website, or with the link below: Link:  https://teams.microsoft.com/l/meetup-...

Arctic Bioscience today announced that a clinical study published in International Ophthalmology demonstrated that daily supplementation with ROMEGA® herring caviar oil resulted in a statistically significant improvement in the visual field measure Mean Deviation (MD) in patients with primary open-angle glaucoma (POAG) and controlled intraocular pressure (IOP). No adverse events were observed, and the treatment was well tolerated. About the study The three-month study included 50 patients. The intervention group received one ROMEGA® capsule (500mg) daily. Results showed a clear...

Arctic Bioscience launches Romega® Skin Refine, a dietary supplement that builds on the company's solid experience with advanced healthcare products, based on herring roe. Our new launch marks our entry into a large, global and growing market segment within “Beauty and Skincare”, with an estimated market size of 550-700 billion USD and growing with an estimated 7-8 % annually. The product is already available on Romega.no, and during the third quarter of 2025 it will be launched in China, in collaboration with our partner Kotler Marketing Group China. The product will also be launched in...

12-month readout of the HeROPA phase 2b clinical trial shows potential through key secondary endpoint PGA 0/1, where the per protocol population approaches significance (p = 0.07) after one year of treatment. Relevant subgroups show statistical significance (p < 0.05). Importantly, HRO350 was well tolerated throughout the study, with no safety concerns or drug-related serious adverse events reported. While the primary endpoint (PASI50 at 26 weeks) in the 52-week placebo-controlled study was not met due to an unexpectedly high placebo response, the overall data support the potential of...

The Annual General Meeting of Arctic Bioscience AS was held Monday 26 May 2025 at 11:00 (CET). All the items on the agenda were addressed and approved. Attached is the minutes of the Annual General Meeting. Changes to the Board of Directors: The General Meeting approved the change in the Board of Directors in accordance with the board's proposal, thus the Board of Directors will consist of the following people: · Harald Nordal (chairperson) · Jan Endre Vartdal · Tore A. F. Tønseth · Marita Holstad · Olav Sindre Kriken This information is subject to the disclosure...